| Literature DB >> 36212472 |
Shu-Hui Hsu1, Zhaohui Han1, Jonathan E Leeman1, Yue-Houng Hu1, Raymond H Mak1, Atchar Sudhyadhom1.
Abstract
Current MRI-guided adaptive radiotherapy (MRgART) workflows require fraction-specific electron and/or mass density maps, which are created by deformable image registration (DIR) between the simulation CT images and daily MR images. Manual density overrides may also be needed where DIR-produced results are inaccurate. This approach slows the adaptive radiotherapy workflow and introduces additional dosimetric uncertainties, especially in the presence of the magnetic field. This study investigated a method based on a conditional generative adversarial network (cGAN) with a multi-planar method to generate synthetic CT images from low-field MR images to improve efficiency in MRgART workflows for prostate cancer. Fifty-seven male patients, who received MRI-guided radiation therapy to the pelvis using the ViewRay MRIdian Linac, were selected. Forty-five cases were randomly assigned to the training cohort with the remaining twelve cases assigned to the validation/testing cohort. All patient datasets had a semi-paired DIR-deformed CT-sim image and 0.35T MR image acquired using a true fast imaging with steady-state precession (TrueFISP) sequence. Synthetic CT images were compared with deformed CT images to evaluate image quality and dosimetric accuracy. To evaluate the dosimetric accuracy of this method, clinical plans were recalculated on synthetic CT images in the MRIdian treatment planning system. Dose volume histograms for planning target volumes (PTVs) and organs-at-risk (OARs) and dose distributions using gamma analyses were evaluated. The mean-absolute-errors (MAEs) in CT numbers were 30.1 ± 4.2 HU, 19.6 ± 2.3 HU and 158.5 ± 26.0 HU for the whole pelvis, soft tissue, and bone, respectively. The peak signal-to-noise ratio was 35.2 ± 1.7 and the structural index similarity measure was 0.9758 ± 0.0035. The dosimetric difference was on average less than 1% for all PTV and OAR metrics. Plans showed good agreement with gamma pass rates of 99% and 99.9% for 1%/1 mm and 2%/2 mm, respectively. Our study demonstrates the potential of using synthetic CT images created with a multi-planar cGAN method from 0.35T MRI TrueFISP images for the MRgART treatment of prostate radiotherapy. Future work will validate the method in a large cohort of patients and investigate the limitations of the method in the adaptive workflow.Entities:
Keywords: MRI-guided therapy; adaptive radiotherapy; deep learning; prostate radiotherapy; synthetic CT
Year: 2022 PMID: 36212472 PMCID: PMC9539763 DOI: 10.3389/fonc.2022.969463
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
CT imaging parameters (simulator model and voxel size), MR imaging parameters (field of view, scan time, voxel size, flip angle, repetition time and echo time), treatment sites and clinical plan information for training and validation/testing datasets.
|
| CT Parameters | SOMATOM – 0.98×0.98×3 mm3 (38) |
| SOMATOM – 1.27×1.27×2 mm3 (1) | ||
| SOMATOM – 1.27×1.27×3 mm3 (4) | ||
| LightSpeed – 0.98×0.98×2.5 mm3 (2) | ||
| MRI Parameters | 50×45×43 cm3– 172 sec (41) | |
| 1.5×1.5×1.5 mm3/60°/3.37 ms/1.45 ms | ||
| 50×45×43 cm3– 25 sec (3) | ||
| 1.5×1.5×3.0 mm3/60°/3 ms/1.27 ms | ||
| 50×30×36 cm3– 173 sec (1) | ||
| 1.5×1.5×1.5 mm3/60°/3.37 ms/1.45 ms | ||
| Treatment Sites | Pelvic Nodes (23) | |
| Prostate (19) | ||
| Perirectal (1) | ||
| Sacrum (1) | ||
| Ureter (1) | ||
|
| CT Parameters | SOMATOM – 0.98×0.98×3 mm3 (10) |
| SOMATOM – 1.27×1.27×3 mm3 (1) | ||
| LightSpeed – 0.98×0.98×2.5 mm3 (1) | ||
| MRI Parameters | 50×45×43 cm3– 172 sec (12) | |
| 1.5×1.5×1.5 mm3/60°/3.37 ms/1.45 ms | ||
| Fractionation | 36.25 Gy in 5 fractions (8) | |
| SIB (36.25, 45 Gy) in 5 fractions (4) | ||
| Number of Beams | 24 – 29 (avoid posterior beams and entering through couch edges) | |
| Number of Monitor Units | 1795 – 3474 MUs per fraction |
Number of patients are indicated in parentheses. SIB, simultaneous integrated boost.
Figure 1(A) A synthetic CT training process using a multi-planar method. Three orthogonal planes from paired MR-CT image sets are used to train generator and discriminator networks with loss functions (L and L). (B) A synthetic CT generation process for validation/testing. A 3D MRI volume is sampled in three orthogonal directions, generating three MRI sets as inputs to the generator. Three corresponding synthetic CT sets are generated (sCTax, sCTcor, sCTsag) and combined to get the final synthetic CT (sCTave).
Figure 2MR (top row), deformed CT (2nd row), sCTax (3rd row), sCTsag (4th row), sCTcor (5th row) and sCTave (bottom row) for one of the validation cases.
MAEs and MEs for whole pelvis and individual segments (air, soft tissue and bone) and PSNRs and SSIMs for whole pelvis.
| Axial (sCTax) | Sagittal (sCTsag) | Coronal (sCTcor) | Average (sCTave) | |
|---|---|---|---|---|
| Whole pelvis (MAE) | 32.8 ± 4.4 | 33.6 ± 4.4 | 33.2 ± 4.4 | 30.1 ± 4.2 |
| Air (MAE) | 406.2 ± 119.3 | 402 ± 131.6 | 409.8 ± 113.7 | 396.5 ± 126.1 |
| Soft tissue (MAE) | 21.6 ± 2.3 | 21.4 ± 2.6 | 21.8 ± 2.9 | 19.6 ± 2.3 |
| Bone (MAE) | 171.7 ± 25.8 | 188.7 ± 25.6 | 175.9 ± 29.9 | 158.5 ± 26.0 |
| Whole pelvis (ME) | -4.3 ± 4.4 | -7.5 ± 4.0 | -7.9 ± 4.2 | -6.8 ± 3.6 |
| Air (ME) | 395.7 ± 122.9 | 381.0 ± 146.7 | 394.8 ± 120.1 | 388.4 ± 131.3 |
| Soft tissue (ME) | 0.7 ± 3.3 | -1.1 ± 2.8 | -2.5 ± 2.4 | -1.2 ± 2.4 |
| Bone (ME) | -115.9 ± 40.9 | -142.5 ± 34.9 | -125.6 ± 43.7 | -128.0 ± 35.2 |
| PSNR | 34.4 ± 1.5 | 33.8 ± 1.4 | 34.0 ± 1.4 | 35.2 ± 1.7 |
| SSIM | 0.9722 ± 0.0031 | 0.9706 ± 0.0047 | 0.9694 ± 0.0053 | 0.9758 ± 0.0035 |
Means, standard deviations and ranges are shown in the table.
Figure 3Isodose color wash (124%, 100%, 69%, 50% and 30% of 36.25 Gy in the prescribed dose) displayed on MR and sCTave images in axial, sagittal and coronal views for the best case (SIB case).
Figure 4Isodose color wash (100%, 69%, 50% and 30% of 36.25 Gy in the prescribed dose) displayed on MR and sCTave images in axial, sagittal and coronal views for the worst case.
Figure 5(A) DVHs for the case shown in and (B) DVHs for the case shown in . Sold lines: dCTcorr; dotted lines: sCTave.
Figure 6Box-and-whisker plots of (A) dose difference (Gy) and (B) relative dose difference (%) between sCTave and dCTcorr for PTV and OAR metrics. The bottom and top of the box represent the 1st and 3rd quartiles; the band inside the box is the median; the ends of the whiskers represent 95% range; the crosses represent outliers.
DVH metrics of dCTcorr and sCTave, the comparison between sCTave and dCTcorr in DVH metrics and 3D gamma analyses with 1%/1 mm and 2%/2 mm in a ROI where the dose is larger than 10% of the maximum dose in each clinical plan.
| dCTcorr (Gy) | sCTave (Gy) | sCTave vs dCTcorr (Gy) | sCTave vs dCTcorr (Relative) | 3D Gamma | ||
|---|---|---|---|---|---|---|
| 1%/1mm | 2%/2mm | |||||
| PTV D95% | 36.11 ± 0.18 | 36.27 ± 0.16 | 0.16 ± 0.11 | 0.5% ± 0.3% | 99.0% ± 0.8% | 99.9% ± 0.1% |
| PTV D2% | 40.83 ± 3.26 | 41.09 ± 3.18 | 0.25 ± 0.14 | 0.6% ± 0.4% | ||
| Rectum D2% | 35.53 ± 1.91 | 35.80 ± 1.94 | 0.27 ± 0.20 | 0.8% ± 0.6% | ||
| Bladder D2% | 35.84 ± 0.75 | 35.98 ± 0.79 | 0.15 ± 0.14 | 0.4% ± 0.4% | ||
| Urethra D2% | 37.95 ± 0.33 | 38.30 ± 0.33 | 0.35 ± 0.15 | 0.9% ± 0.4% | ||